In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Evaluation of lipoprotein-associated phospholipase A2 levels in association with carotid atherosclerosis in patients with coronary artery disease

Session Poster session 1

Speaker Guzyaliya Osmankulova

Event : ESC Congress 2017

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Coronary Artery Disease (Chronic)
  • Session type : Poster Session

Authors : G Osmankulova (Bishkek,KG), BT Kurmanbekova (Bishkek,KG), AM Noruzbaeva (Bishkek,KG)

Authors:
G. Osmankulova1 , B.T. Kurmanbekova1 , A.M. Noruzbaeva1 , 1National Centre of Cardiology and Therapy - Bishkek - Kyrgyzstan ,

Citation:
European Heart Journal ( 2017 ) 38 ( Supplement ), 199-200

Introduction: Since atherosclerosis is a generalized process that takes place simultaneously in many vascular beds, state of the carotid arteries is seen as a predictor of the risk of serious cardiovascular events (strokes, heart attacks). Lipoprotein-associated phospholipase A2 (Lp-PLA2) is specific for vascular inflammation, and informs inflammation in the atherosclerotic plaque and its degree of stability. Detection of relationship between Lp-PLA2 levels and the atherosclerotic plaque presence in carotid arteries would be an additional criterion to specify severity and progression of the atherosclerotic process.

Purpose: To evaluate Lp-PLA2 levels in association with carotid atherosclerosis in patients with coronary artery disease.

Methods: 136 patients with verified coronary artery disease (stable angina, functional class III) were examined (average age was 55,4±5,9). Depending on the presence or absence of atherosclerotic plaques in carotid arteries and their amounts, all patients were divided into 3 groups: 1 group (n=46) – patients without carotid atherosclerosis, 2 group (n=42) – patients with 1 atherosclerotic plaque in carotid arteries, 3 group (n=48) – patients with 2 and more atherosclerotic plaques in carotid arteries. Concentration of Lp-PLA2 was determined through the “PLAC” test, “DiaDexus” company, USA. Duplex scanning of carotid arteries performed by standart method on the “Sequoia-512” apparatus, “Acuson” company (USA).

Results: Average levels of Lp-PLA2 was significantly higher in patients with 2 and more atherosclerotic plaques in carotid arteries, than in patients without carotid atherosclerosis (p=0,001), as well as total cholesterol (p=0,001) and low-density lipoprotein cholesterol (LDL-C) levels (p=0,001). Such duplex scanning indicators as intima-media thickness in systole, intima-media thickness increasing, carotid stenosis degree, significantly different between groups with and without atherosclerotic plaques in carotid arteries (p=0,001, p=0,025 and p=0,001, respectively). Correlation analysis detect statistically significant positive correlations between Lp-PLA2 levels and total cholesterol (p=0,000, p=0,01, p=0,001, respectively); between Lp-PLA2 levels and LDL-C (p=0,000, p=0,03, p=0,000, respectively) in all 3 groups. Besides, it was determined that Lp-PLA2 levels positively correlates with intima-media thickness of carotid arteries increasing in patients of 2 and 3 groups (p=0,03 and p=0,000, respectively), which is not found in 1 group, where patients were without carotid atherosclerosis.

Conclusion: A significant relationship between elevated Lp-PLA2 and the degree of carotid stenosis, and increased levels of total cholesterol, LDL-C. Elevated levels of Lp-PLA2 in serum, combined with the presence of increasing the degree of carotid stenosis, levels of total cholesterol, LDL-C, can be considered as probable risk factor for cardiovascular events.

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are